National Clinical Trials Network Research at the University of Wisconsin

项目摘要/摘要 威斯康星大学碳骨癌中心(UWCCC)、其领导层和教职员工是由一个 通过在癌症教育、预防中快速应用开创性研究战胜癌症的使命 和治疗。UWCCC的战略计划中嵌入了扩展现代研究平台的策略 包括全面的临床研究计划和模范的数据管理和临床试验 优先次序以及科学的监督和领导。UWCCC NCTN绕过多学科团队 仍然是这一战略计划不可或缺的组成部分，并与主要教职员工合作支持创新 NCI国家临床试验网络中下一代临床试验的转译研究。 自1974年以来，UWCCC的教职员工一直担任NCI癌症合作小组发展的领导者 计划；首先是在经社理事会内，然后在21世纪初与RTOG、ACOSOG和GOG合作。作为NCI和它的 NCTN在2014年过渡到集中式基础设施，UWCCC设计了一个LAPS团队 主要研究人员通过结合现有的广泛的科学领导，来自三个主要合作机构 集团(经社理事会/ACRIN、NRG和联盟)。这是一种多学科的方法，由外科、 医疗、放射和妇科肿瘤学促进了创新的治理结构，以提供 领导和监督II/III期临床试验的优先顺序、及时启动试验和稳健的应计费用 以及对肿瘤临床研究感兴趣的年轻教员的发展。在我们上个月以来的四年里 在提交赠款后，UWCCC LAPS团队为重要的基因指导临床提供了支持 试验以及那些专注于先进成像的试验，同时加强我们癌症中心的基础设施。 本UG1申请寻求对在UWCCC内继续NCTN活动的支持。这种伙伴关系 仍然是为不同人群的癌症患者提供新疗法的重要机制 方法，以及为现有的和新的领导人提供资源和支持的手段 NCTN将创新的翻译项目引入第二/第三阶段临床试验。

Project Summary/Abstract The University of Wisconsin Carbone Cancer Center (UWCCC), its leadership, and its faculty are driven by a mission to defeat cancer through rapid application of groundbreaking research in cancer education, prevention and treatment. Embedded in the UWCCC's strategic plan are tactics for expanding a modern research platform inclusive of a comprehensive clinical research program with exemplary data management and clinical trial prioritization as well as scientific oversight and leadership. The UWCCC NCTN LAPs multi-disciplinary team remains an integral component of this strategic initiative and collaborates with key faculty to support innovative translational research for next generation clinical trials within the NCI's National Clinical Trials Network. Since 1974, UWCCC faculty have functioned as leaders in the development of the NCI cancer cooperative group program; first within ECOG and then with RTOG, ACOSOG and GOG in the early 2000s. As the NCI and its NCTN transitioned to a centralized infrastructure in 2014, the UWCCC designed a LAPS team of collaborative principal investigators by combining the existing broad scientific leadership from three of the primary cooperative groups (ECOG/ACRIN, NRG and ALLIANCE). This multi-disciplinary approach with leaders from Surgical, Medical, Radiation and Gynecologic Oncology, facilitated an innovative governance structure to provide leadership and oversight in prioritization of Phase II/III clinical trials, timely trial activation and robust accrual as well as the development of junior faculty interested in oncologic clinical research. In the four years since our last grant submission, the UWCCC LAPS team has provided support for the important genomically-directed clinical trials as well as those with a focus on advanced imaging, while strengthening our Cancer Center's infrastructure. This UG1 application seeks support for continuing the NCTN activities within the UWCCC. This partnership remains an important mechanism for providing a diverse population of cancer patients with novel treatment approaches, as well as a means for providing resources and support for existing and new leaders within the NCTN to bring innovative translational projects to Phase II/III clinical trials.